Overview

This trial is active, not recruiting.

Conditions rectum cancer, cancer of colon
Treatment genetic analysis on tumor kept in tumor bank
Sponsor Assistance Publique - Hôpitaux de Paris
Collaborator Institut National de la Santé Et de la Recherche Médicale, France
Start date November 2013
End date November 2018
Trial size 597 participants
Trial identifier NCT02458664, 2013-A01080-45, NI12029

Summary

We collect prospectively and retrospectively, patients' demographic, pathological, surgical, therapeutic and prognosis informations in a database. After patient's consent to collect tumoural samples of their colorectal cancer after resection.

We will then be able to evaluate the impact of HSP110, a chaperon protein, on their prognosis. Other proteins (to be determined) will also be study, after.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Arm
All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital
genetic analysis on tumor kept in tumor bank

Primary Outcomes

Measure
Recurrence free survival and Recurrence free survival after resection of the colon cancer
time frame: End of follow up : at least 3 years

Secondary Outcomes

Measure
Overall survival
time frame: End of follow up : at least 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - All patients undergoing curative colorectal cancer in general and digestive surgery department at Saint-Antoine hospital. - Patients reporting their non-opposition to the use of tissue samples taken from their specimen for research purposes. Exclusion Criteria: - Patients who did not report their non-opposition to the use of tissue samples taken from their specimen for research purposes.

Additional Information

Official title BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer
Description To investigate the importance of HSP110DE9 as a prognostic marker for colorectal cancer, we will analyze genotyping fluorescence quantitative RT-PCR and / or immunomarquage the presence of this mutant in a large cohort of patients (more than 2000 patients had or having a colorectal cancer). All patients have been or will be made in general and digestive surgery department at Saint-Antoine hospital. Tumor fragments samples were or will be made on their tumor and keep it in the tumor bank of the Saint-Antoine hospital. All patients reported their no objection to the use of these tumor fragments for research purposes. A database will be built and correlated with the tumor fragments. This project is intended that the constitution of a clinical database including prognostic so that we make discoveries on HSP110DE9 or other molecular biology to discover markers can be correlated with clinical data. In the absence of other studies on the subject, with no real knowledge of the prognostic impact of this mutant, we cannot provide an effective computation. We therefore propose to make a database of 2000 patients retrospectively and prospectively to obtain statistical results valid and powerful.
Trial information was received from ClinicalTrials.gov and was last updated in November 2015.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.